True North Labs

Author: labstruenorth@gmail.com

  • GV1001 Peptide Shows Promise Against Neurodegeneration in Alzheimer’s Mouse Study

    Researchers have published encouraging findings in Experimental & Molecular Medicine describing how GV1001, a peptide derived from human telomerase reverse transcriptase, was able to rescue signs of neurodegeneration in a mouse model of Alzheimer’s disease. The study adds to a growing body of research exploring how peptide-based approaches might one day help address the underlying biology of neurodegenerative conditions rather than just their symptoms.

    GV1001 has an interesting history: it was originally studied as a cancer vaccine candidate because of its connection to telomerase activity, but scientists have increasingly discovered that this same peptide appears to have protective effects on cells under stress, including neurons. In this latest mouse study, the peptide appeared to counteract markers of neurodegeneration, suggesting it may help preserve brain cell health or function in the presence of Alzheimer’s-related pathology.

    What makes this finding particularly exciting is the possibility that a single peptide with a well-characterized safety profile from prior cancer research could be repurposed for an entirely different and pressing medical need. Alzheimer’s disease remains one of the most challenging conditions in medicine, with limited treatment options that meaningfully alter its course. Any research pointing toward new mechanisms of neuroprotection is a welcome development for the field.

    While this work was conducted in mice and will need to be followed by further research, including studies to confirm how GV1001 exerts its protective effects and whether similar benefits could translate to humans, it represents a meaningful step forward. Peptide-based therapeutics continue to expand into new therapeutic areas, and findings like this help illustrate the versatility of these molecules beyond their original intended use.

    As with all early-stage research, continued studies will be needed to fully understand GV1001’s potential role in neurodegenerative disease. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease | Experimental & Molecular Medicine – Nature

  • FDA Advisory Panel Backs Expanded Access to Compounded Peptides

    FDA Advisory Panel Backs Expanded Access to Compounded Peptides

    In a notable step for the peptide therapeutics space, an FDA advisory panel has voted in favor of adding certain peptides to the list of substances permitted for pharmacy compounding. This decision, if it moves forward through the FDA’s broader regulatory process, could open the door for licensed compounding pharmacies to prepare these peptide formulations for patients under physician guidance.

    Compounding pharmacies play an important role in the U.S. healthcare system, often providing personalized formulations when commercially manufactured products don’t meet a specific patient’s needs—whether due to dosage requirements, allergies to inactive ingredients, or supply shortages. Adding peptides to this permitted list represents a meaningful expansion of the tools available to prescribers and compounders working to meet patient needs.

    The panel’s vote reflects growing recognition within regulatory circles of the therapeutic potential peptides offer across multiple areas of medicine, from metabolic health to recovery and beyond. While the FDA’s own scientific staff reportedly expressed some reservations during the discussion—a normal part of the rigorous, multi-perspective review process the agency uses—the panel ultimately determined that the potential benefits to patient access warranted moving forward. This kind of thorough deliberation, weighing diverse expert viewpoints, is exactly the kind of careful process that helps build a responsible regulatory framework for emerging therapies.

    For the peptide community, this development signals continued momentum toward greater legitimacy and accessibility. As the compounding landscape evolves, patients working with knowledgeable healthcare providers may find more options available to them, supported by pharmacies operating under FDA-recognized standards rather than in regulatory gray areas.

    It’s worth noting that this vote is a recommendation, and the FDA will need to take further steps before any changes to the compounding list become official. As always, we’ll continue to follow this story as it develops. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists – The Hill

  • FDA Panel Gives Nod to 6 Peptides, Signaling Path Forward for Access

    In a development that peptide enthusiasts and researchers have been watching closely, an FDA advisory panel recently reviewed and backed six peptide compounds, offering a potential glimpse into how these increasingly popular substances may be regulated going forward. While advisory panel recommendations are not final rulings, they often carry significant weight in shaping the agency’s eventual decisions and can signal a more defined regulatory pathway for compounds that have existed in something of a gray area.

    Peptides have surged in popularity over recent years, both in clinical research settings and among consumers interested in wellness and recovery applications. However, much of that growth has occurred without the kind of clear regulatory framework that helps ensure consistency, quality, and safety across the market. A formal review process—especially one resulting in support from an expert panel—suggests movement toward more structured oversight, which many in the field see as a net positive for both innovation and consumer confidence.

    For companies developing peptide-based products and for researchers studying their potential applications, panel endorsements like this one can serve as an encouraging signal. Clearer regulatory guidance often translates into more predictable pathways for further study, funding, and eventual product development. It can also help legitimate manufacturers distinguish themselves in a marketplace that has sometimes been muddied by inconsistent quality control.

    While specifics of which six peptides received backing and the exact scope of the panel’s recommendations matter a great deal for those following this space closely, the broader takeaway is one of forward motion. Advisory panels typically weigh available safety and efficacy data before offering their support, meaning this step reflects a level of scientific scrutiny that can ultimately benefit the field by weeding out weaker candidates while allowing more promising compounds to advance.

    As with any regulatory process, next steps will likely include further agency review, potential public comment periods, and eventual rulemaking or guidance documents. True North Labs will continue to monitor how this panel’s recommendations translate into concrete policy, as clearer rules of the road for peptides could open new doors for research, product development, and responsible consumer access alike.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: An FDA Panel Just Backed 6 Peptides—Here’s What to Know – EatingWell

  • Peptide Vaccine SurVaxM Explored Alongside Chemotherapy for Newly Diagnosed Glioblastoma

    Researchers are advancing a Phase II clinical trial examining a novel peptide-based approach to treating glioblastoma, one of the most aggressive forms of brain cancer. The trial, registered on ClinicalTrials.gov, is testing whether SurVaxM, a vaccine therapy built from the survivin peptide or antigen, can work alongside the standard chemotherapy drug temozolomide to improve outcomes for newly diagnosed patients.

    The concept behind SurVaxM is rooted in harnessing the body’s own immune system. Survivin is a protein commonly overexpressed in many cancer cells, including glioblastoma tumors, but largely absent in healthy adult tissue. By training the immune system to recognize and target cells expressing survivin, the vaccine aims to help the body mount a more precise and effective attack against the tumor, potentially complementing the tumor-fighting mechanisms of chemotherapy.

    Temozolomide already plays a well-established role in glioblastoma treatment, working to stop cancer cells from dividing and spreading. This trial is designed to determine whether pairing it with the survivin-targeted vaccine offers additional benefit compared to chemotherapy alone, and to further characterize the safety profile of the combination approach. Studies like this represent an important step in exploring how peptide immunotherapies might be integrated into established cancer treatment regimens.

    Approaches that combine immune-based peptide therapies with conventional treatments reflect a broader and encouraging trend in oncology research: leveraging the precision of peptides to target cancer-specific markers while continuing to build on proven therapies. Glioblastoma remains a challenging diagnosis, and research initiatives like this one contribute valuable data toward developing more effective, well-tolerated treatment combinations for patients in the future.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

  • New Clinical Trial Explores Inhaled Epigenetic Therapy Combined With Immunotherapy for Early-Stage Lung Cancer

    New Clinical Trial Explores Inhaled Epigenetic Therapy Combined With Immunotherapy for Early-Stage Lung Cancer

    Researchers at the National Institutes of Health have launched a new clinical trial investigating an innovative combination approach for people with early-stage, operable non-small cell lung cancer (NSCLC). The study, known as AZA-AEGEAN, pairs an inhaled form of the epigenetic drug azacytidine with the already-approved neoadjuvant regimen of durvalumab and platinum-based chemotherapy, exploring whether this combined epigenetic-immunotherapy strategy can further improve outcomes before surgery.

    NSCLC remains the most common form of lung cancer, and while surgery is the standard treatment for early-stage disease, tumors can sometimes return even after successful removal. Durvalumab plus chemotherapy given before surgery is already an FDA-approved option shown to help some patients, but researchers are now asking whether adding inhaled azacytidine could offer an additional benefit by targeting cancer cells directly in the lungs.

    What makes this approach particularly promising is the delivery method: rather than delivering azacytidine intravenously, as it is used in other approved indications, the trial uses a nebulized, inhaled version similar to an asthma inhaler mist. This route is designed to concentrate the drug’s effects directly in lung tissue while limiting how much enters the bloodstream, potentially reducing systemic exposure while still working to sensitize tumor cells epigenetically before the immune-boosting and chemotherapy components take effect.

    The trial is carefully structured to gather robust data, including pre- and post-treatment biopsies, imaging, and bronchial fluid collection, allowing researchers to closely study how the combination affects tumor tissue at a cellular level. Participants will undergo three treatment cycles before their planned surgery, followed by regular monitoring for up to three years afterward, an approach that should provide valuable long-term insight into how this regimen influences recurrence and recovery.

    This type of research represents an encouraging step in the ongoing effort to refine and personalize treatment for early-stage lung cancer, potentially opening the door to more effective pre-surgical options that combine multiple therapeutic strategies. While it is still early days for this specific combination, trials like this help build the foundation for future advances in thoracic oncology care. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) – a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

  • New Phase I Trial Explores Bipolar Androgen Therapy for Advanced Prostate Cancer

    Researchers have launched a phase I clinical trial investigating a novel approach called bipolar androgen therapy (BAT) for patients with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that has stopped responding to standard hormone-lowering treatments. The trial, registered on ClinicalTrials.gov, aims to explore whether deliberately cycling testosterone levels between very low and very high points in the body can help re-sensitize cancer cells to androgen deprivation therapy.

    Bipolar androgen therapy works by alternating testosterone exposure between castration levels—lower than what the body normally produces—and supraphysiological levels, which are higher than typical. This unconventional strategy is based on the idea that rapidly shifting hormone levels may confuse or stress prostate cancer cells that have adapted to survive in a low-testosterone environment, potentially making them vulnerable again to treatments that were previously effective.

    The phase I study will primarily examine changes in androgen receptor sensitivity, along with safety and early signs of effectiveness. Researchers will monitor prostate-specific antigen (PSA) levels, a key biomarker used to track prostate cancer activity, to see whether the therapy can help suppress cancer cell growth and potentially delay disease progression in this hard-to-treat patient population.

    This research represents an encouraging step forward for patients with mCRPC, a stage of prostate cancer that often presents significant treatment challenges once resistance to standard therapies develops. If bipolar androgen therapy proves both safe and effective at restoring treatment sensitivity, it could open new avenues for combination treatment strategies, potentially extending the usefulness of existing androgen deprivation therapies rather than requiring entirely new drug classes.

    Early-phase trials like this one are essential building blocks in cancer research, helping scientists understand whether creative, mechanism-based approaches can translate into real clinical benefit. As this study progresses, it will contribute valuable data to the broader effort to improve outcomes for men facing advanced prostate cancer. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

  • New Clinical Trial Explores Antibody-Drug Conjugate Combination for Advanced Cervical Cancer

    New Clinical Trial Explores Antibody-Drug Conjugate Combination for Advanced Cervical Cancer

    A new clinical trial, known as MK-2870-036 (also called TroFuse-036, GOG-3123, and ENGOT-cx22), is now underway to explore innovative treatment options for people living with metastatic cervical cancer. The study focuses on a promising combination approach: pairing an antibody-drug conjugate called sacituzumab tirumotecan (sac-TMT, also known as MK-2870) with the immunotherapy drug pembrolizumab, and in some cases, the targeted therapy bevacizumab.

    Antibody-drug conjugates represent an exciting frontier in cancer treatment because they are designed to precisely target cancer cells while sparing healthy tissue. Sac-TMT works by attaching to specific markers found on cancer cells and delivering its therapeutic payload directly to those cells, potentially offering a more focused approach compared to traditional chemotherapy.

    This trial is particularly encouraging because it is being conducted as a first-line maintenance treatment study, meaning researchers are looking at how this combination might help patients continue to do well after their initial cancer treatment. The study will compare outcomes between patients receiving the new combination therapy and those receiving standard treatment, with a focus on both safety and how well patients tolerate the combined medicines.

    Key goals of the research include understanding whether this combination approach helps people live longer overall, and whether it can delay cancer progression compared to current standard treatments. The inclusion of bevacizumab as an optional component in some treatment arms also allows researchers to explore multiple therapeutic strategies within a single, well-designed study framework.

    This type of collaborative, multi-institutional research effort—spanning multiple international study groups including GOG and ENGOT—reflects the ongoing commitment of the oncology research community to find better treatment options for patients facing metastatic cervical cancer. Trials like this one are essential steps in the process of bringing new, potentially more effective therapies to patients who need them.

    This article is for informational purposes only and is not intended as medical advice. Individuals interested in clinical trials should consult with their healthcare provider.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  • New Phase 2 Trial Launches to Target KRAS G12D-Mutated Pancreatic Cancer

    New Phase 2 Trial Launches to Target KRAS G12D-Mutated Pancreatic Cancer

    A newly registered Phase 2 clinical trial is set to explore the safety and effectiveness of VS-7375, an investigational therapy designed to target tumors driven by the KRAS G12D mutation, in patients with metastatic pancreatic cancer. The study will examine VS-7375 both as a standalone treatment and in combination with cetuximab, an established therapy already used in several cancer treatment regimens.

    Pancreatic cancer remains one of the most challenging cancers to treat, and mutations in the KRAS gene—particularly the G12D variant—are among the most common genetic drivers of the disease. For years, KRAS mutations were considered extremely difficult to target with precision therapies, so the continued development of drugs like VS-7375 represents meaningful progress in the effort to bring targeted treatment options to patients who currently have limited choices.

    By testing VS-7375 both alone and alongside cetuximab, researchers aim to learn whether combining approaches could enhance treatment response compared to single-agent therapy. This kind of combination strategy is common in oncology research, as it allows scientists to explore whether pairing therapies with different mechanisms of action can improve outcomes for patients with aggressive, hard-to-treat tumors.

    The advancement of this trial into Phase 2 signals that earlier research supported enough safety and preliminary activity to justify further investigation in a larger patient population. While much work remains before any conclusions can be drawn about long-term efficacy, the initiation of this study reflects the broader momentum in precision medicine—where treatments are increasingly designed to match the specific genetic profile of a patient’s tumor rather than relying on one-size-fits-all approaches.

    For patients and families affected by KRAS G12D-mutated pancreatic cancer, the launch of new targeted studies like this one offers a hopeful sign that research in this area continues to move forward. As with all investigational treatments, results from this trial will need to be thoroughly reviewed before any conclusions can be made about its safety or effectiveness. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

  • Peptide Vaccine PolyPEPI1018 Advances to Phase II Trial in Combination with Immunotherapy for Colorectal Cancer

    Peptide Vaccine PolyPEPI1018 Advances to Phase II Trial in Combination with Immunotherapy for Colorectal Cancer

    A promising new clinical trial is investigating whether a peptide-based cancer vaccine can enhance the effectiveness of immunotherapy in patients battling advanced colorectal cancer. The multicenter, open-label phase II study is testing the combination of PolyPEPI1018, an experimental peptide vaccine, with atezolizumab, an established immunotherapy drug, in patients with microsatellite stable (MSS) colorectal cancer who have already progressed through two or three prior treatment regimens.

    This patient population represents one of the more challenging groups in oncology. MSS colorectal cancers have historically shown limited responsiveness to immunotherapy alone, making the search for combination approaches especially important. By pairing a peptide vaccine designed to stimulate a targeted immune response with an immune checkpoint inhibitor, researchers hope to give the body’s own defenses a better chance at recognizing and attacking cancer cells that have proven resistant to standard therapies.

    The trial’s design reflects a thorough, methodical approach to patient safety and scientific rigor. Researchers will be closely monitoring not only the safety and tolerability of the combination treatment but also its immunogenicity — meaning how effectively the vaccine provokes a meaningful immune response — as well as early signs of clinical activity against the tumors. This structured evaluation is a foundational step that, if successful, could pave the way for larger trials and eventually broader treatment options for colorectal cancer patients who currently have few remaining choices.

    What makes this development particularly encouraging is the innovative use of peptide vaccine technology in a cancer type that has been difficult to treat with immunotherapy alone. Peptide vaccines like PolyPEPI1018 are designed to train the immune system to recognize specific markers on cancer cells, potentially offering a more targeted and personalized approach to treatment. Combining this strategy with an already-approved immunotherapy agent represents the kind of thoughtful, incremental scientific progress that often leads to meaningful advances in patient care.

    While it will take time to gather and analyze results from this trial, its very existence signals continued momentum in the peptide research field and a genuine effort to expand treatment possibilities for patients facing limited options. Trials like this one are essential building blocks toward future therapies, and the colorectal cancer community will be watching closely for updates as the study progresses.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on treatment options.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

  • New Clinical Trial Explores Growth Hormone Therapy for Children with Achondroplasia

    A new clinical trial listed on ClinicalTrials.gov is set to evaluate the efficacy and safety of recombinant human growth hormone (rhGH) in children diagnosed with achondroplasia, the most common form of dwarfism. This research represents an important step forward in understanding how existing therapies might be optimized to support growth and development in children affected by this genetic condition.

    Achondroplasia affects skeletal development and can present unique medical and quality-of-life challenges for children and their families. While recombinant human growth hormone has been studied and used in various growth-related conditions for years, this trial aims to gather more specific data on its effects in the achondroplasia population, potentially helping clinicians make more informed decisions about treatment approaches.

    Clinical trials like this one are a vital part of the medical research process. By carefully evaluating both efficacy and safety in a controlled study setting, researchers can build a more robust evidence base that may eventually inform treatment guidelines. This kind of methodical, safety-conscious approach reflects the broader trend in pediatric endocrinology toward evidence-based care tailored to specific genetic and developmental conditions.

    For families navigating an achondroplasia diagnosis, ongoing research of this nature offers a sense of forward momentum. Every well-designed clinical trial adds to the collective medical knowledge that can shape future care options, and studies focused on pediatric populations are conducted with particular attention to safety monitoring throughout the research process.

    As the peptide and growth hormone research space continues to expand, trials like this highlight the importance of rigorous science in addressing the needs of specific patient communities. We look forward to following the progress of this study and sharing updates as more information becomes available.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance specific to any medical condition or treatment.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia